Home Tags Kadcyla

Tag: Kadcyla

Daiichi Sankyo

FDA Approves Trastuzumab Deruxtecan for Adult Patients with Unresectable or Metastatic...

The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with unresectable or metastatic HER2...

The Rise of HER2-targeting ADCs and the Journey from Breakthrough Therapy...

Antibody-drug conjugates (ADCs) as precision targeted cancer therapies have started to deliver on their early promise as an innovative novel drug modality as demonstrated...
ESMO 2017 - 3

Trastuzumab Deruxtecan Receives Breakthrough Therapy Designation for HER2+ Metastatic Breast Cancer...

The U.S. Food and Drug Administration (FDA) has granted trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca), a HER2 directed antibody-drug conjugate (ADC), Breakthrough Therapy...

First Patients Dosed in Phase II Trial with Trastuzumab Duocarmazine in...

A first patient has started treatment in a Phase II study designed to evaluate the safety and efficacy of trastuzumab duocarmazine, also known...

U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a...

San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,675,358 entitled "Antibody Adjuvant...

HER2-targeting Trastuzumab Deruxtecan Shows Promise in Patients with Non-breast/Gastric Cancers

Results from a phase I study investigating fam-trastuzumab deruxtecan-nxki (formerly known as DS-8201a; Enhertu®; Daiichi Sankyo and AstraZeneca) showed signs of clinical activity of...

Ado-trastuzumab emtansine (Kadcyla®)

International Nonproprietary Names (INN) Ado-trastuzumab emtansine Prescription Drug Yes Class Antineoplastic Agents US Brand Name Kadcyla® Other names ado-trastuzumab emtansine, trastuzumab-DM1, T-DM1 Available as a generic drug No Marketing Authorization Genentech/Roche United States Adopted Name (USAN) Trastuzumab...

Ado-trastuzumab emtansine Approved for the Treatment of Early Breast Cancer

In early May 2019, the United States Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kadcyla®, Genentech/Roche; T-DM1) for the adjuvant treatment of patients...

Four Ways to Show Nonobviousness of ADC Inventions

As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.

Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...

This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...

X